12:00 AM
Sep 10, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Iluvien regulatory update

pSivida said the U.K.'s NICE rescheduled the second appraisal committee meeting to discuss chronic diabetic macular edema (DME) drug Iluvien fluocinolone acetonide intravitreal implant after the agency accepted additional data for review from a subgroup of DME patients. NICE issued draft guidance last month recommending against the use of Iluvien in the indication (see BioCentury, Aug....

Read the full 259 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >